Cycling South Africa is the governing body of cycling in South Africa and is a member of the Union Cycliste Internationale (UCI). It is affiliated to the South African Sports Confederation and Olympic Committee (SASCOC) as well as the Department of Sport & Recreation. Cycling South Africa regulates the five major disciplines within the sport, both amateur and professional, which include: Road Cycling, Mountain Biking, BMX Biking, Track Cycling and Para-Cycling. Cycling South Africa’s “2020 Vision” strategy, to cater for both the elite cyclist as well as the everyday two- and three-wheel lovers, contributes to the organisation being a dynamic, successful and highly respected governing body of cycling, at both National and International level. Cycling South Africa is committed to transformation and development of the sport and making it accessible to all via its development programmes.
In Study 2, randomization assigned 208 patients to receive ZINBRYTA (150 mg) and 204 patients to receive placebo; 91% of ZINBRYTA patients and 91% of placebo patients completed treatment. At baseline, the mean age of patients was 36 years, the mean disease duration since diagnosis was years, the mean EDSS score was , and the mean number of relapses in the prior year was . At baseline, 65% of patients were female, 48% of patients had MRI scans with T1 Gd-enhancing lesions and 21% of patients had previously taken one or more non-steroid treatments for MS.
Common (1% to 10%): Sinusitis, nasopharyngitis, upper respiratory tract infection, bronchitis
Uncommon (% to 1%): Cough, dyspnea, snoring, dysphonia
Rare (less than %): Pulmonary microembolism (POME) (cough, dyspnea, malaise, hyperhidrosis, chest pain, dizziness, paresthesia, or syncope) caused by oily solutions
Frequency not reported: Sleep apnea
Postmarketing reports: Chest pain, asthma, chronic obstructive pulmonary disease, hyperventilation, obstructive airway disorder, pharyngeal edema, pharyngolaryngeal pain, pulmonary embolism, respiratory distress, rhinitis, sleep apnea syndrome [ Ref ]